Fate Therapeutics, Verio deal

Fate acquired Verio for an undisclosed amount. Fate said Verio's biologics capabilities and preclinical programs complement its pipeline of stem cell modulators. Verio's pipeline includes candidates for promoting the growth of new insulin-producing beta cells to treat diabetes and for regenerating cardiomyocytes following heart attack to treat severe cardiac dysfunction. ...